BAN2401 (Humanized anti-amyloid beta mab)
Developed by Biogen in collaboration with Eisai Co., Ltd.
The most common cause of dementia, Alzheimer’s disease is a brain disorder that leads to impairment of intellectual functions and social skills, resulting ultimately in significant disturbance of daily living activities. Dementia is caused by the destruction of cells in certain parts of the brain primarily involved in memory and mental function.
How this therapy could help:
The memory loss and functionality decline of Alzheimer’s disease have been linked to amyloid plaques, abnormal protein deposits that build up in the brain. BAN2401 is an antibody that binds to amyloid, which could reduce its presence in the brain and potentially slow the progress of the disease. See more information about the study here http://www.reuters.com/article/2015/03/20/us-biogen-alzheimers-idUSKBN0MG1OU20150320.